AbbVie (ABBV) AGM 2026 summary

Opening remarks and agenda

• Meeting opened by the Chairman and CEO, with all directors and executive management present.

• Agenda included election of directors, auditor ratification, executive compensation, elimination of supermajority voting, and a shareholder proposal.

Financial performance review

• Achieved record net sales of $61.2 billion, exceeding expectations by over $2 billion.

• Adjusted EPS reached $10.54, above guidance midpoint, with 8.6% sales growth.

• R&D investment increased, funding about 90 clinical programs.

Board and executive committee updates

• Dr. Robert J. Alpern stepped down as director; appreciation expressed for his service.